AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16556248 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs in the premenstrual phase on stress
Number of subjects: 32
Study 11870241 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg oral daily)
Number of subjects: 532
Study 9618623 — intervention group
Group type: EXPERIMENTAL
Intervention: Active enforcement program
Number of subjects: 319
Study 9618623 — intervention group
Group type: COMPARATOR
Intervention: Non-enforcement communities
Number of subjects: 319
Study 7715976 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional instruction on infant feeding (overlearning)
Number of subjects: 40
Study 7715976 — intervention group
Group type: COMPARATOR
Intervention: Standard infant feeding instruction
Number of subjects: 40
Study 2533450 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg three times a day)
Number of subjects: 0
Study 2533450 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MPA (100 mg/day)
Number of subjects: 0
Study 2533450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2533450 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study 2533450 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 0
Study 2533450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (Danazol and MPA)
Number of subjects: 0
Study 46021 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical relaxation exercises
Number of subjects: 20
Study 46021 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched hypertensive controls)
Number of subjects: 20
Study 7368759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazoline
Number of subjects: 0
Study 7368759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazedone
Number of subjects: 0
Study 30572070 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management for 48 hours (TTM48)
Number of subjects: 79
Study 30572070 — intervention group
Group type: COMPARATOR
Intervention: Standard targeted temperature management for 24 hours (TTM24)
Number of subjects: 79
Study 29389155 — intervention group
Group type: EXPERIMENTAL
Intervention: PHAT Life intervention
Number of subjects: 310
Study 29389155 — intervention group
Group type: COMPARATOR
Intervention: Health promotion program (control)
Number of subjects: 310
Study 26176344 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine + atazanavir (ABC/3TC + ATV)
Number of subjects: 296
Study 26176344 — intervention group
Group type: COMPARATOR
Intervention: tenofovir/emtricitabine + atazanavir/ritonavir (TDF/FTC + ATV/r)
Number of subjects: 296
Study 25138607 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (n = 8)
Number of subjects: 17
Study 25138607 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 9)
Number of subjects: 17
Study 22504933 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel S (homeopathic remedy)
Number of subjects: 181
Study 22504933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 22504933 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel S
Number of subjects: 181
Study 19508712 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management programme for insulin titration
Number of subjects: 248
Study 19508712 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 248
Study 17991639 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed children
Number of subjects: 2482
Study 17991639 — intervention group
Group type: COMPARATOR
Intervention: Nonbreastfed children
Number of subjects: 2482
Study 15365700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HRT)
Number of subjects: 80
Study 15365700 — intervention group
Group type: COMPARATOR
Intervention: Control group (original exercise intervention)
Number of subjects: 80
Study 15365700 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 80
Study 11875727 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT (Docetaxel 100 mg/m² plus FEC 75) alternated for eight courses
Number of subjects: 136
Study 11875727 — intervention group
Group type: EXPERIMENTAL
Intervention: SEQ T (Four courses of Docetaxel 100 mg/m² followed by four courses of FEC 75)
Number of subjects: 136
Study 11875727 — intervention group
Group type: EXPERIMENTAL
Intervention: SEQ F (Four courses of FEC 75 followed by four courses of Docetaxel 100 mg/m²)
Number of subjects: 136
Study 11875727 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 136
Study 11875727 — intervention group
Group type: COMPARATOR
Intervention: ALT
Number of subjects: 136
Study 11875727 — intervention group
Group type: COMPARATOR
Intervention: SEQ T
Number of subjects: 136
Study 11875727 — intervention group
Group type: COMPARATOR
Intervention: SEQ F
Number of subjects: 136
Study 10086937 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Synacthen test (LDST)
Number of subjects: 32
Study 10086937 — intervention group
Group type: COMPARATOR
Intervention: Standard short Synacthen test (SSST)
Number of subjects: 32
Study 10086937 — intervention group
Group type: COMPARATOR
Intervention: 08:00 hour serum cortisol concentration
Number of subjects: 32
Study 10086937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement
Number of subjects: 32
Study 7596731 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential AOD curriculum
Number of subjects: 44
Study 7596731 — intervention group
Group type: COMPARATOR
Intervention: No formal training (Control)
Number of subjects: 44
Study 2193496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine 360 mg daily
Number of subjects: 22
Study 2193496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 22
Study 342218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 39
Study 30959528 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 150
Study 30959528 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Treatment (GT)
Number of subjects: 150
Study 30959528 — intervention group
Group type: COMPARATOR
Intervention: Self-Administered Individual Treatment (SIT)
Number of subjects: 150
Study 30959528 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 29084585 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting low- or high-normal PaCO2, PaO2, and MAP for 36 hours after ICU admission
Number of subjects: 120
Study 23955196 — intervention group
Group type: COMPARATOR
Intervention: Resin sealant
Number of subjects: 52
Study 23955196 — intervention group
Group type: COMPARATOR
Intervention: Laser irradiation (50 mJ, 10 Hz, 0.5 W)
Number of subjects: 52
Study 23955196 — intervention group
Group type: EXPERIMENTAL
Intervention: APF + laser
Number of subjects: 52
Study 23955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish + laser
Number of subjects: 52
Study 22782464 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard prophylactic antibiotic administration
Number of subjects: 355
Study 22782464 — intervention group
Group type: COMPARATOR
Intervention: Extended prophylactic antibiotic administration
Number of subjects: 355
Study 22021141 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified percutaneous vertebroplasty (Group A)
Number of subjects: 70
Study 22021141 — intervention group
Group type: COMPARATOR
Intervention: Traditional percutaneous vertebroplasty (Group B)
Number of subjects: 70
Study 19390796 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (EMLA)
Number of subjects: 150
Study 19390796 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian classical instrumental music (raaga‐Todi)
Number of subjects: 150
Study 19390796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 150
Study 17531921 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation Index (AI)
Number of subjects: 152
Study 15087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Native Escherichia coli asparaginase (9 doses during induction)
Number of subjects: 1001
Study 15087948 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase (6 or 10 doses)
Number of subjects: 1001
Study 15087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Native asparaginase continued in Ab-positive patients without clinical allergies
Number of subjects: 1001
Study 15087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analysis of 280 patients followed for 30 months
Number of subjects: 1001
Study 11840364 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical dialysis dose (equilibrated Kt/V = 1.30 +/- 0.22)
Number of subjects: 1000
Study 10920945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy via implanted drug delivery system (DDS), administered once every 1 or 2 weeks (Group A)
Number of subjects: 82
Study 10920945 — intervention group
Group type: COMPARATOR
Intervention: One bolus arterial infusion chemotherapy, administered once every month (Group B)
Number of subjects: 82
Study 8078115 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of vitamin D a day
Number of subjects: 255
Study 8078115 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of vitamin D a day
Number of subjects: 255
Study 8078115 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D a day
Number of subjects: 255
Study 2685707 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment (TT)
Number of subjects: 107
Study 2685707 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 107
Study 790537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine-containing gel
Number of subjects: 37
Study 790537 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 37
Study 30898984 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate training (3 times/week) on cyclometers for 3 months
Number of subjects: 31
Study 30898984 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in murine model (5 times/week, 1 hour) for 2 weeks before and 1.5 weeks after minipumps implantation
Number of subjects: 31
Study 28528348 — intervention group
Group type: EXPERIMENTAL
Intervention: Home oxygen plus home NIV (median oxygen flow rate, 1.0 L/min; inspiratory positive airway pressure of 24 cm H2O; expiratory positive airway pressure of 4 cm H2O; backup rate of 14 breaths/minute)
Number of subjects: 116
Study 28528348 — intervention group
Group type: COMPARATOR
Intervention: Home oxygen alone (median oxygen flow rate, 1.0 L/min)
Number of subjects: 116
Study 28528348 — intervention group
Group type: EXPERIMENTAL
Intervention: Home oxygen plus home NIV
Number of subjects: 116
Study 28528348 — intervention group
Group type: COMPARATOR
Intervention: Home oxygen alone
Number of subjects: 116
Study 25636714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 138
Study 25636714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 24002370 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 40 mg
Number of subjects: 27
Study 24002370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21924874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 30
Study 21924874 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 30
Study 21924874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin (XELOX)
Number of subjects: 2034
Study 18421053 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil/folinic acid plus oxaliplatin (FOLFOX‐4)
Number of subjects: 2034
Study 16463795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 16463795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 16463795 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 12723055 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR network for blood concentration prediction
Number of subjects: 32
Study 12723055 — intervention group
Group type: EXPERIMENTAL
Intervention: Committee of trained networks for blood concentration prediction
Number of subjects: 32
Study 12723055 — intervention group
Group type: EXPERIMENTAL
Intervention: Elman network for dosage prediction
Number of subjects: 32
Study 11206597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily for 12 weeks or 25 mg daily for 10 weeks)
Number of subjects: 664
Study 11206597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 664
Study 8692558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin
Number of subjects: 0
Study 8692558 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 0
Study 1916617 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-week training program for myocardial infarction patients with moderate-to-severe left-ventricular dysfunction.
Number of subjects: 0
Study 1916617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 0
Study 6647203 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral labetalol
Number of subjects: 0
Study 6647203 — intervention group
Group type: COMPARATOR
Intervention: 10 mg intramuscular hydralazine
Number of subjects: 0
Study 31673364 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA and DNase
Number of subjects: 210
Study 31673364 — intervention group
Group type: COMPARATOR
Intervention: t‐PA and placebo
Number of subjects: 210
Study 31673364 — intervention group
Group type: COMPARATOR
Intervention: DNase and placebo
Number of subjects: 210
Study 31673364 — intervention group
Group type: COMPARATOR
Intervention: double placebo
Number of subjects: 210
Study 31673364 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA
Number of subjects: 210
Study 30314978 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/d
Number of subjects: 7020
Study 30314978 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/d
Number of subjects: 7020
Study 30314978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 28762124 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm with serum PSA determination, multi-kallikrein panel, and mpMRI for biopsy decision.
Number of subjects: 67000
Study 28762124 — intervention group
Group type: COMPARATOR
Intervention: Control arm with no intervention.
Number of subjects: 67000
Study 25672513 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vaccination booster group
Number of subjects: 78
Study 25672513 — intervention group
Group type: COMPARATOR
Intervention: Single vaccination group
Number of subjects: 78
Study 25672513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pre-vaccination titers)
Number of subjects: 78
Study 23228503 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 Agile Patch applied to the lower abdomen
Number of subjects: 24
Study 23228503 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 Agile Patch applied to the buttock
Number of subjects: 24
Study 23228503 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 Agile Patch applied to the upper torso
Number of subjects: 24
Study 23228503 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 Agile Patch (all sites)
Number of subjects: 24
Study 20003064 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant milk formula supplemented with 6 g/l short‐chain galacto‐ and long‐chain fructo‐oligosaccharides (scGOS/lcFOS, ratio 9:1)
Number of subjects: 215
Study 20003064 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (control group)
Number of subjects: 215
Study 20003064 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding (reference group)
Number of subjects: 215
Study 18678845 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 0
Study 18678845 — intervention group
Group type: COMPARATOR
Intervention: No screening for prostate cancer
Number of subjects: 0
Study 17030757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 210
Study 17030757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 210
Study 17030757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 210
Study 17030757 — intervention group
Group type: COMPARATOR
Intervention: Dopamine agonist nontreated group (Control)
Number of subjects: 210
Study 12604744 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-centered methods
Number of subjects: 2
Study 12604744 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 2
Study 12604744 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider referral and face-to-face contact
Number of subjects: 2
Study 12604744 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced recruiter or community recruiter
Number of subjects: 2
Study 10802364 — intervention group
Group type: EXPERIMENTAL
Intervention: (60)C0 photon beam
Number of subjects: 392
Study 10802364 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 MV photon beam
Number of subjects: 392
Study 10802364 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MV photon beam
Number of subjects: 392
Study 10802364 — intervention group
Group type: COMPARATOR
Intervention: (60)C0, 4 MV, or 6 MV
Number of subjects: 392
Study 9036213 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate aerosol (MS)
Number of subjects: 49
Study 9036213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8381259 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 31
Study 8381259 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 31
Study 3690807 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent metoclopramide (2 mg/kg x 4)
Number of subjects: 35
Study 3690807 — intervention group
Group type: COMPARATOR
Intervention: Combination metoclopramide and dexamethasone
Number of subjects: 35
Study 31665898 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection into the muscle and skin layers immediately after wound closure
Number of subjects: 24
Study 31665898 — intervention group
Group type: COMPARATOR
Intervention: No PRP injection (Control)
Number of subjects: 24
Study 29958267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide in combination with dexamethasone
Number of subjects: 0
Study 29958267 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib in combination with dexamethasone
Number of subjects: 0
Study 27046458 — intervention group
Group type: COMPARATOR
Intervention: Face-down positioning (FDP)
Number of subjects: 81
Study 27046458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupine positioning (NSP)
Number of subjects: 81
Study 25519828 — intervention group
Group type: EXPERIMENTAL
Intervention: Reablement (experimental group)
Number of subjects: 60
Study 25519828 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 60
Study 25247709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose MQ (15 mg/kg)
Number of subjects: 4749
Study 25247709 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 4749
Study 22775229 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%/Timolol 0.5% (LT)
Number of subjects: 18
Study 22775229 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%/Timolol 0.5% (BT)
Number of subjects: 18
Study 19633693 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranilast and artificial tears (q.i.d.)
Number of subjects: 18
Study 19633693 — intervention group
Group type: COMPARATOR
Intervention: Topical artificial tears, sodium hyaluronate, and vitamin A
Number of subjects: 18
Study 17432645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application using a cake made by Sanleng, Ezhu, Dahuang, and Bingpian applied at Tianshu (ST 25), Qihai (CV 6), Guanyuan (CV 4)
Number of subjects: 42
Study 17432645 — intervention group
Group type: COMPARATOR
Intervention: Congrong Tongbian Oral Liquid (control group)
Number of subjects: 42
Study 17432645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application
Number of subjects: 42
Study 16115944 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) combined with vaccinations using CEA-derived CAP-1 peptide with adjuvants (CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2, CAP-1/dSLIM/IL-2, CAP-1/IL-2) for three cycles followed by weekly vaccinations until progression of disease.
Number of subjects: 17
Study 16115944 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination treatment
Number of subjects: 17
Study 16115944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 17
Study 11849865 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 24
Study 10094146 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration tones presented to subjects
Number of subjects: 70
Study 10094146 — intervention group
Group type: COMPARATOR
Intervention: Standard tones presented to subjects
Number of subjects: 70
Study 8804877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 20 mg/kg/day for 6 months
Number of subjects: 15
Study 8804877 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 cystic fibrosis patients with liver disease)
Number of subjects: 15
Study 8804877 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 cystic fibrosis patients without liver disease)
Number of subjects: 15
Study 1361803 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilizer
Number of subjects: 66
Study 1361803 — intervention group
Group type: COMPARATOR
Intervention: Tape
Number of subjects: 66
Study 1361803 — intervention group
Group type: COMPARATOR
Intervention: Non-immobilized group
Number of subjects: 66
Study 6142645 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg three times a day, titrated to a maximum dose of 12 mg per day)
Number of subjects: 100
Study 6142645 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (10 mg three times a day, titrated to a maximum dose of 120 mg per day)
Number of subjects: 100